GRI Bio (NASDAQ:GRI) highlighted newly reported Phase 2A data for its lead idiopathic pulmonary fibrosis (IPF) program during a healthcare-focused Corporate Connect event, outlining safety results, biomarker trends, and early lung function signals that the company believes support continued development. President, CEO, and Director Marc Hertz also discussed a separate pipeline program aimed at autoimmune […]